TABLE 2.
The diagnostic value of 12 TAAbs for identifying BC from healthy control (HC)
| TAAb | Cut‐off (ng/mL) | Positive(%) | χ2 | P | Se (%) | Sp (%) | YI | Accuracy (%) | FPR (%) | FNR (%) | PPV (%) | NPV (%) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BC | HC | ||||||||||||
| (n = 399) | (n = 399) | ||||||||||||
| ALK | 26 911 | 94 (23.6) | 40 (10.0) | 26.153 | <.001 | 23.6 | 90.0 | 0.1 | 16.8 | 10.0 | 76.4 | 70.2 | 54.1 |
| BRCA2 | 22 292 | 118 (29.6) | 38 (9.5) | 50.994 | <.001 | 29.6 | 90.5 | 0.2 | 19.5 | 9.5 | 70.4 | 75.7 | 56.2 |
| CDKN2A | 24 963 | 100 (25.1) | 40 (10.0) | 31.185 | <.001 | 25.1 | 90.0 | 0.2 | 17.5 | 10.0 | 74.9 | 71.5 | 54.6 |
| CEBPA | 23 449 | 147 (36.8) | 42 (10.5) | 76.437 | <.001 | 36.8 | 89.5 | 0.3 | 23.7 | 10.5 | 63.2 | 77.8 | 58.6 |
| CEP55 | 43 553 | 91 (22.8) | 40 (10.0) | 23.755 | <.001 | 22.8 | 90.0 | 0.1 | 16.4 | 10.0 | 77.2 | 69.5 | 53.8 |
| FUBP1 | 19 421 | 102 (25.6) | 42 (10.5) | 30.505 | <.001 | 25.6 | 89.5 | 0.2 | 18.0 | 10.5 | 74.4 | 70.9 | 54.6 |
| GATA3 | 19 858 | 196 (49.1) | 41 (10.3) | 144.197 | <.001 | 49.1 | 89.7 | 0.4 | 29.7 | 10.3 | 50.9 | 82.7 | 63.8 |
| HIST1H3B | 35 877 | 83 (20.8) | 41 (10.3) | 16.843 | <.001 | 20.8 | 89.7 | 0.1 | 15.5 | 10.3 | 79.2 | 66.9 | 53.1 |
| HRAS | 32 356 | 127 (31.8) | 40 (10.0) | 57.319 | <.001 | 31.8 | 90.0 | 0.2 | 20.9 | 10.0 | 68.2 | 76.1 | 56.9 |
| IMP2/p62 | 35 344 | 133 (33.3) | 40 (10.0) | 63.833 | <.001 | 33.3 | 90.0 | 0.2 | 21.7 | 10.0 | 66.7 | 76.9 | 57.4 |
| PTCH1 | 34 216 | 177 (44.4) | 39 (9.8) | 120.888 | <.001 | 44.4 | 90.2 | 0.3 | 27.1 | 9.8 | 55.6 | 81.9 | 61.9 |
| RalA | 49 331 | 117 (29.3) | 40 (10.0) | 47.014 | <.001 | 29.3 | 90.0 | 0.2 | 19.7 | 10.0 | 70.7 | 74.6 | 56.0 |
The cut‐off value was considered as the maximum Youden index at the point of more than 90% specificity.
FNR, false‐negative rate; FPR, false‐positive rate; NPV, negative predictive value; PPV, positive predictive value; Se, sensitivity; Sp, specificity; YI, Youden index.